Novel Antibody Demonstrates Promise against Asthma – Genetic Engineering News

Novel Antibody Demonstrates Promise against Asthma
Genetic Engineering News
Scientists at St. Joseph's Healthcare Hamilton and McMaster University report that they successfully tested an antibody (AMG 157) that can improve the quality of life for individuals with asthma by relieving inflammation in the lungs. The study
Amgen drug for allergy asthma shows promise in early testsSFGate
Novel Biologic Promising for Allergic AsthmaMedPage Today
New antibody can improve quality of life for individuals with asthmaNews-Medical.net
Daily Digest –CTV News
all 27 news articles »

View full post on asthma – Google News

Novel Biologic Promising for Allergic Asthma – MedPage Today


CTV News

Novel Biologic Promising for Allergic Asthma
MedPage Today
SAN DIEGO — A novel first-in-class biologic agent targeting allergic inflammation appeared promising for allergen-induced asthma in a phase IIb trial. AMG 157, an anti-thymic stromal lymphopoietin (TSLP) humanized monoclonal antibody, reduced most …
Researchers discover new potential antibody treatment for asthmaMedical Xpress
Canadian study finds potential antibody treatment for mild asthmaCTV News
Hamilton researchers discover potential asthma treatmentHamilton Spectator

all 11 news articles »

View full post on asthma – Google News

For Severe Asthma, Most Surveyed U.S. Payers Would Reimburse a Novel … – PR Newswire (press release)

For Severe Asthma, Most Surveyed U.S. Payers Would Reimburse a Novel
PR Newswire (press release)
Surveyed U.S. and European pulmonologists agree that reduction in rate of exacerbations is the attribute that most influences prescribing decisions in moderate to severe asthma. Clinical data and the opinions of interviewed thought leaders indicate

View full post on asthma – Google News

Novel community program to improve the way childhood asthma controlled … – News-Medical.net

Novel community program to improve the way childhood asthma controlled
News-Medical.net
Indiana University School of Medicine emergency medicine faculty hope to improve the way childhood asthma is medically managed in Marion County through an innovative program that incorporates the skills and flexible schedules of specially trained 

View full post on asthma – Google News

iSonea Launches Novel Smartphone Device for Asthma Patients – TopNews United States


SBS

iSonea Launches Novel Smartphone Device for Asthma Patients
TopNews United States
A new technology has been launched by the Medical technology firm iSonea. This is basically a smartphone device, which will help asthma patients monitor their condition. This AirSonea device, when placed near the base of the throat, changes into a 
Smartphone asthma device launched in AustraliaAustralian Techworld
Cathy Freeman backs the use of technology in treating asthmaSBS
Freeman reveals asthma struggleYahoo!7 News
Herald Sun –Proactive Investors Australia
all 7 news articles »

View full post on asthma – Google News

Diffusion lung capacity of carbon monoxide: A novel marker of airways remodeling in asthmatic children?

Diffusion lung capacity of carbon monoxide: A novel marker of airways remodeling in asthmatic children?

Allergy Rhinol (Providence). 2012;3(2):e66-73

Authors: Piacentini GL, Tezza G, Cattazzo E, Kantar A, Ragazzo V, Boner AL, Peroni DG

Abstract
Asthma is universally considered a chronic inflammatory disorder of the airways. Several noninvasive markers, such as exhaled nitric oxide (FeNO) and exhaled breath temperature (PletM), have been proposed to evaluate the degree of airway inflammation and remodeling in asthmatic children. The aim of this study was to evaluate the relationship between diffusion lung capacity of carbon monoxide (DLCO) and these inflammatory markers in asthmatic children. We compared data of FeNO, PletM, and DLCO collected in 35 asthmatic children at admission (T0) and discharge (T1) after a period spent in a dust-mite-free environment (Misurina, Italian Dolomites, 1756 m). PletM showed a reduction from 29.48°C at T0 to 29.13°C at T1 (p = 0.17); DLCO passed from 93 to 102 (p = 0.085). FeNO mean value was 29.7 ppb at admission and 18.9 ppb at discharge (p = 0.014). Eosinophil mean count in induced sputum was 4 at T0 and 2 at T1 (p = 0.004). Spearman standardization coefficient beta was 0.414 between eosinophils and FeNO and -0.278 between eosinophils and DLCO. Pearson’s correlation index between DLCO and PletM was -0.456 (p = 0.019). A negative correlation between DLCO and PletM was found. However, DLCO did not show a significant correlation with FeNO and eosinophils in the airways. Additional studies are needed to clarify the role of DLCO as a potential tool in monitoring childhood asthma.

PMID: 23342292 [PubMed – in process]

View full post on pubmed: asthma

Aerocrine’s novel asthma test in search of doctors, insurers [The News … – Insurance News Net (press release)

Aerocrine's novel asthma test in search of doctors, insurers [The News
Insurance News Net (press release)
With $22 million in cash, Aerocrine is positioned to finance operations through 2012, according to one analyst report, putting a premium on increased sales for its relatively unknown asthma test. The 15-year-old company, based on a scientific discovery

View full post on asthma – Google News